CD274 and esophageal adenocarcinoma: It is reported that the PD-L1 positivity rate in esophageal adenocarcinoma is only 18%, whereas the PD-L1 positivity rate in ESCC is approximately 44%, suggesting that ESCC may be more responsive to immunotherapy [39].